Section Arrow
UPB.NASDAQ
- Upstream Bio Inc
Quotes are at least 15-min delayed:2025/09/05 22:10 EDT
Regular Hours
Last
 19.97
+0.29 (+1.47%)
Day High 
20.42 
Prev. Close
19.68 
1-M High
21.03 
Volume 
556.22K 
Bid
16
Ask
31.87
Day Low
19.09 
Open
19.81 
1-M Low
15.05 
Market Cap 
1.06B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 17.99 
20-SMA 17.66 
50-SMA 14.49 
52-W High 29.4599 
52-W Low 5.14 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.18/-2.64
Enterprise Value
1.06B
Balance Sheet
Book Value Per Share
7.58
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.21M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GNPXGenprex0.2295+0.0738+47.40%0.18PE
ADAPAdaptimmune Therapeutics plc0.041-0.01-19.61%-- 
NUVBNuvation Bio3.9+0.48+14.04%-- 
KLTOKlotho Neurosciences Inc0.4851-0.0099-2.00%-- 
IOVAIovance Biotherapeutics2.49+0.29+13.18%-- 
Quotes are at least 15-min delayed:2025/09/05 22:10 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.